Hypertension Clinical Trial
| NCT number | NCT01184599 |
| Other study ID # | OCGH-746 |
| Secondary ID | |
| Status | Recruiting |
| Phase | Phase 4 |
| First received | August 16, 2010 |
| Last updated | June 23, 2011 |
| Start date | June 2010 |
The purpose of this study is to evaluate the effect of aliskiren, a novel direct rennin inhibitor, on renal function and progress of renal disease in hypertensive patients with IgA nephropathy.
| Status | Recruiting |
| Enrollment | 30 |
| Est. completion date | |
| Est. primary completion date | March 2013 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 16 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - IgA nephropathy confirmed by renal biopsy - Hypertension (<= 125/75 mmHg) Exclusion Criteria: - Patients who have been treated with angiotensin type 1 receptor blocker or angiotensin-converting enzyme inhibitor within 4 weeks - Severe hypertension (<= 180/110 mmHg) or secondary hypertension - Patients with history of allergy or adverse effect for aliskiren - Renal dysfunction (estimated Glomerular Filtration Rate < 60 mL/min/1.73m2) - Pregnancy - Patient treated with cyclosporine - Hyperkalemia (serum potassium >= 5.6 mmol/L) - Autoimmune disease including systemic lupus erythematosus - Patients inadequate for the study |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Japan | Kurume University, School of Medicine | Fukuoka | |
| Japan | Department of Internal Medicine, Osaka City General Hospital | Osaka | |
| Japan | Kinki University, Faculty of Medicine | Osaka | |
| Japan | Ohno memorial Hospital | Osaka |
| Lead Sponsor | Collaborator |
|---|---|
| Kagawa University |
Japan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Renal function (Creatinine clearance) | One year (every 6 months) | No | |
| Primary | Urinary protein | One year (every 6 months) | No | |
| Secondary | Urinary angiotensinogen | One year (every 6 months) | No | |
| Secondary | Urinary type 4 collagen | One year (every 6 months) | No | |
| Secondary | Urinary Transforming growth factor-beta | One year (every 6 months) | No | |
| Secondary | High-sensitivity C-reactive protein | One year (every 6 months) | No | |
| Secondary | Plasma Rennin Activity | One year (every 12 months) | No | |
| Secondary | Aldosterone | One year (every 12 months) | No | |
| Secondary | Asymmetric dimethylarginine | One year (every 12 months) | No | |
| Secondary | Advanced glycation end product | One year (every 12 months) | No | |
| Secondary | (Pro)renin receptor | One year (every 12 months) | No | |
| Secondary | Oxidative stress | One year (every 12 months) | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
| Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
| Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
| Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
| Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
| Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
| Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
| Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
| Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
| Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
| Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
| Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
| Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
| Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
| Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |